BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31688627)

  • 1. Prednisolone Prophase for a Week Versus Upfront Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia: An Analysis With Reference to Induction Mortality in a Developing Country.
    Jabbar N; Mansoor N; Nadeem K; Maqsood MSc S; Butt Z; Ashraf S
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):181-184. PubMed ID: 31688627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
    Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
    Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.
    Yetgin S; Gürgey A; Tuncer AM; Cetin M; Ozbek N; Sayli T; Güler E; Kara A; Olcay L; Duru F; Gümrük F; Atahan L; Tunçbilek E
    Leuk Res; 1998 Jun; 22(6):485-93. PubMed ID: 9678714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.
    Schmiegelow K; Nyvold C; Seyfarth J; Pieters R; Rottier MM; Knabe N; Ryder LP; Madsen HO; Svejgaard A; Kaspers GJ
    Leukemia; 2001 Jul; 15(7):1066-71. PubMed ID: 11455975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Leading causes of death during the induction therapy in pediatric patients with acute lymphoblastic leukemia].
    Aguilar-Hernández M; Fernández-Castillo G; Núñez-Villegas NN; Pérez-Casillas RX; Núñez-Enríquez JC
    Rev Med Inst Mex Seguro Soc; 2017; 55(3):286-291. PubMed ID: 28440981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China.
    Gao YJ; Lu FJ; Wang HS
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):798-802. PubMed ID: 17164648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
    Liang DC; Hung IJ; Yang CP; Lin KH; Chen JS; Hsiao TC; Chang TT; Pui CH; Lee CH; Lin KS
    Leukemia; 1999 Feb; 13(2):155-60. PubMed ID: 10025887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
    Janiszewska H; Styczynski J; Kolodziej B; Wysocki M; Haus O
    Ann Hematol; 2009 Dec; 88(12):1193-8. PubMed ID: 19352661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015.
    Zhu Y; Yang R; Cai J; Yu J; Tang Y; Chen Y; Wang N; He H; Wu X; Cheng FWT; Sun L; He Y; Ju X; Tian X; Hu Q; Jin R; Pan K; Fang Y; Zhai X; Jiang H; Li CK
    Cancer Med; 2020 Mar; 9(6):2113-2121. PubMed ID: 31994344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
    Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
    J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia.
    Nemes K; Csóka M; Nagy N; Márk Á; Váradi Z; Dankó T; Kovács G; Kopper L; Sebestyén A
    Pathol Oncol Res; 2015 Jul; 21(3):597-604. PubMed ID: 25388103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
    Hazar V; Karasu GT; Uygun V; Akcan M; Küpesiz A; Yesilipek A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):e317-22. PubMed ID: 20930649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
    Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-agent induction/consolidation therapy for childhood acute lymphoblastic leukemia: an Indian experience.
    Advani SH; Iyer RS; Pai SK; Gopal R; Saikia TK; Nair CN; Kurkure PA; Nadkarni KS; Pai VR
    Am J Hematol; 1992 Apr; 39(4):242-8. PubMed ID: 1553952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
    Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
    Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.